Outcome | Men | Women | p value for multiplicative interaction | ICR | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Model 1† | Model 2†† | Model 1† | Model 2†† | |||||||
Warfarin | DOAC | Warfarin | DOAC | Warfarin | DOAC | Warfarin | DOAC | |||
Heart failure | ||||||||||
Events/N | 4799/54,192 | 355/8461 | 4799/54,192 | 355/8461 | 4149/49,845 | 312/8130 | 4149/49,845 | 312/8130 | 0.89 | 0.02 |
HR (95% CI) | 1 (ref.) | 0.81 (0.73, 0.91) | 1 (ref.) | 0.94 (0.84, 1.05) | 1 (ref.) | 0.82 (0.73, 0.92) | 1 (ref.) | 0.93 (0.83, 1.04) | ||
Stroke | ||||||||||
Events/N | 1328/54,411 | 93/8487 | 1328/54,411 | 93/8487 | 1766/50,031 | 140/8155 | 1766/50,031 | 140/8155 | 0.3 | 0.119 |
HR (95% CI) | 1 (ref.) | 0.85 (0.69, 1.05) | 1 (ref.) | 0.89 (0.72, 1.10) | 1 (ref.) | 1.00 (0.84, 1.19) | 1 (ref.) | 1.01 (0.86, 1.22) | ||
Major bleeding | ||||||||||
Events/N | 3390/54,315 | 286/8481 | 3390/54,315 | 286/8481 | 3066/49,981 | 273/8144 | 3066/49,981 | 273/8144 | 0.56 | 0.063 |
HR (95% CI) | 1 (ref.) | 0.99 (0.88, 1.12) | 1 (ref.) | 1.01 (0.89, 1.14) | 1 (ref.) | 0.99 (0.87, 1.12) | 1 (ref.) | 1.03 (0.90, 1.16) |